Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
FHL-1 CRISPR/Cas9 KO Plasmid (h): sc-403541
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FHL-1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the FHL-1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: FHL-1 Antibody (H-4): sc-374246
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FHL-1 CRISPR/Cas9 KO Plasmid (h) | sc-403541 | 20 µg | $397.00 |
Overview
FHL1 encodes four-and-a-half LIM domains protein 1 (FHL-1), a LIM-only adaptor protein enriched in striated muscle that scaffolds multiprotein complexes at the sarcomere and costamere. FHL-1 coordinates cytoskeletal organization, mechanotransduction, and transcriptional outputs by coupling structural proteins to signaling nodes implicated in muscle differentiation and remodeling. Altered FHL1 function is associated with inherited myopathies and cardiomyopathies, where disrupted protein–protein interactions can perturb sarcomeric integrity and stress-response pathways. In addition to muscle biology, FHL-1 has been used as a model for studying LIM-domain–mediated assembly of signaling complexes and context-dependent regulation of gene expression.
FHL-1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the FHL1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the FHL1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the FHL1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish FHL-1 protein expression.
This CRISPR knockout system enables efficient generation of FHL1-deficient cell models for investigation of FHL-1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting FHL1 exon(s) critical for FHL-1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple FHL1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by FHL-1 CRISPR/Cas9 KO Plasmid (h) and FHL-1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the FHL1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by FHL-1 HDR Plasmid (h) and FHL-1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by FHL1 homology arms to support homology-directed repair at defined FHL1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.